Total Funding
95
87
Total FundingSeries B raised
Growth Score
20 pts
Heat Score
12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
1731
Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
- Danny Wells: Scientific Founder / Founding Team
- Noam Solomon: CEO and co-founderPast Role: Gloat, Head of Data
About the Company
Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system.
Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample,
and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment.
The company is located in New York City, San Francisco, and Tel Aviv, Israel.
